Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: GlobeNewswire
BRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, recently announced findings from a real-world study evaluating the clinical and economic impact of EXPAREL® (bupivacaine liposome injectable suspension) on opioid use, healthcare resource utilization, and total medical costs following outpatient total hip arthroplasty among Medicare patients. The data were presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hosted by the American Society of Regional Anesthesia and Pain Medicine (ASRA), held from April 16-18. The retrospective study evaluated the real-world impact of EXPAREL compared to other standard-of-care options (non-liposome bupivacaine (non-LB)) on opioid use and healthcare utilization for up to 12 months following outpatient total hip arthroplasty for Medicare patients. Data was anal
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to ShareholdersGlobeNewswire
- Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty [Yahoo! Finance]Yahoo! Finance
- Can New EXPAREL Data and Proxy Fight Outcomes Reshape the Case For Investing In Pacira (PCRX)? [Yahoo! Finance]Yahoo! Finance
- Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026GlobeNewswire
- Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresGlobeNewswire
PCRX
Earnings
- 2/26/26 - Miss
PCRX
Sec Filings
- 4/30/26 - Form PRRN14A
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form ARS
- PCRX's page on the SEC website